BR112013007385A2 - leptinas altamente solúveis - Google Patents
leptinas altamente solúveis Download PDFInfo
- Publication number
- BR112013007385A2 BR112013007385A2 BR112013007385-3A BR112013007385A BR112013007385A2 BR 112013007385 A2 BR112013007385 A2 BR 112013007385A2 BR 112013007385 A BR112013007385 A BR 112013007385A BR 112013007385 A2 BR112013007385 A2 BR 112013007385A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- chimeric polypeptide
- leptin
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (32)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38740210P | 2010-09-28 | 2010-09-28 | |
US61/387,402 | 2010-09-28 | ||
US42209110P | 2010-12-10 | 2010-12-10 | |
US61/422,091 | 2010-12-10 | ||
PCT/US2011/053774 WO2012050925A2 (en) | 2010-09-28 | 2011-09-28 | Highly soluble leptins |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013007385A2 true BR112013007385A2 (pt) | 2021-04-20 |
BR112013007385B1 BR112013007385B1 (pt) | 2022-07-26 |
Family
ID=45938879
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013007385-3A BR112013007385B1 (pt) | 2010-09-28 | 2011-09-28 | Polipeptídeo quimérico, seu uso e composição que o compreende |
BR112013007388-8A BR112013007388B1 (pt) | 2010-09-28 | 2011-09-28 | Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende |
BR122021020041-6A BR122021020041B1 (pt) | 2010-09-28 | 2011-09-28 | Polipeptídeo quimérico, seu uso e composição que o compreende |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013007388-8A BR112013007388B1 (pt) | 2010-09-28 | 2011-09-28 | Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende |
BR122021020041-6A BR122021020041B1 (pt) | 2010-09-28 | 2011-09-28 | Polipeptídeo quimérico, seu uso e composição que o compreende |
Country Status (14)
Country | Link |
---|---|
US (6) | US20130203661A1 (pt) |
EP (4) | EP2621515B1 (pt) |
JP (5) | JP6174489B2 (pt) |
CN (2) | CN103547590B (pt) |
BR (3) | BR112013007385B1 (pt) |
CA (3) | CA2813038C (pt) |
CY (2) | CY1119023T1 (pt) |
DK (3) | DK3241558T3 (pt) |
EA (2) | EA032917B1 (pt) |
ES (3) | ES2630031T3 (pt) |
MX (2) | MX351128B (pt) |
PL (1) | PL3241558T3 (pt) |
PT (2) | PT2621519T (pt) |
WO (2) | WO2012050930A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2933262T3 (en) | 2010-07-09 | 2018-06-25 | Affibody Ab | polypeptides |
WO2012050930A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc | Engineered polypeptides having enhanced duration of action |
WO2013009539A1 (en) * | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action and reduced immunogenicity |
WO2013148966A1 (en) * | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
CN111763247A (zh) | 2012-09-25 | 2020-10-13 | 阿菲博迪公司 | 白蛋白结合多肽 |
AU2014254019B2 (en) | 2013-04-18 | 2018-09-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
WO2014204816A2 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
CA2920679A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
MX2016005915A (es) | 2013-11-11 | 2016-12-16 | Armo Biosciences Inc | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. |
US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
JP6728141B2 (ja) | 2014-09-04 | 2020-07-22 | ノヴォ ノルディスク アー/エス | 新規のアミリン及びカルシトニン受容体アゴニスト |
AU2015333827A1 (en) | 2014-10-14 | 2017-04-20 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
CA2963995A1 (en) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
CN113201049B (zh) | 2015-08-05 | 2022-10-04 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
US10023581B2 (en) | 2015-09-22 | 2018-07-17 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
CA3000275A1 (en) | 2015-10-02 | 2017-04-06 | University Of Copenhagen | Small molecules blocking histone reader domains |
HUE063647T2 (hu) | 2016-09-12 | 2024-01-28 | Amryt Pharmaceuticals Inc | Eljárások anti-leptin semlegesítõ antitestek detektálására |
WO2018140956A1 (en) * | 2017-01-30 | 2018-08-02 | Alexion Pharmaceuticals, Inc. | Monovalent anti-properdin antibodies and antibody fragments |
AU2019251580A1 (en) * | 2018-04-13 | 2020-10-08 | Massachusetts Institute Of Technology | Engineered treatments for hair repair and long-lasting color retention |
WO2023049357A2 (en) * | 2021-09-24 | 2023-03-30 | The Uab Research Foundation | Control of subunit stoichiometry in single-chain msp nanopores |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
GEP20033145B (en) | 1989-10-16 | 2003-12-25 | Amgen Inc | Stem Cell Factor |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
WO1992017505A1 (en) | 1991-04-05 | 1992-10-15 | Board Of Regents Of The University Of Washington | Monoclonal antibodies to stem cell factor receptors |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
US6048837A (en) | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
EP0836620A1 (en) | 1995-01-31 | 1998-04-22 | Eli Lilly And Company | Anti-obesity proteins |
US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
AU4766596A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Ob gene product antibodies |
US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
AU4766196A (en) * | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Anti-obesity proteins |
US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
AU5539596A (en) | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
US5840517A (en) * | 1995-04-26 | 1998-11-24 | Eli Lilly And Company | Process for preparing obesity protein analogs |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE741187T1 (de) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
EP0826045A1 (en) | 1995-05-08 | 1998-03-04 | Chiron Corporation | Nucleic acids for treating obesity |
CA2221824A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
EP0832220A1 (en) | 1995-06-07 | 1998-04-01 | Amgen Inc. | Ob protein compositions and method |
US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
JPH11508134A (ja) | 1995-06-22 | 1999-07-21 | イーライ・リリー・アンド・カンパニー | 肥満症蛋白質中間体およびその製法と使用 |
GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
WO1997002004A2 (en) * | 1995-06-30 | 1997-01-23 | Eli Lilly And Company | Methods for treating diabetes |
DK0865294T3 (da) | 1995-08-17 | 2004-06-28 | Amgen Inc | Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater |
WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
ES2217327T3 (es) | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
WO1997020933A2 (en) | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
WO1997026916A1 (en) | 1996-01-25 | 1997-07-31 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
US6025324A (en) | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
IL127153A0 (en) | 1996-06-06 | 1999-09-22 | Smithkline Beecham Plc | Fragments of leptin (ob protein) |
US5922678A (en) | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
CA2263826A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
CZ90999A3 (cs) | 1996-09-20 | 1999-06-16 | Hoechst Aktiengesellschaft | Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu |
WO1998016545A1 (en) | 1996-10-11 | 1998-04-23 | Eli Lilly And Company | Therapeutic proteins |
WO1998024896A2 (en) | 1996-12-06 | 1998-06-11 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
DK0954588T3 (da) | 1996-12-20 | 2007-05-14 | Amgen Inc | OB fusionsprotein-sammensætninger og fremgangsmåder |
US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
AU6569998A (en) * | 1997-03-20 | 1998-10-12 | Eli Lilly And Company | Obesity protein formulations |
TR199902980T2 (xx) | 1997-06-06 | 2000-05-22 | Smithkline Beecham P.L.C. | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. |
DE69828287T2 (de) | 1997-06-13 | 2005-12-15 | Gryphon Therapeutics, Inc., South San Francisco | Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen |
DE69942453D1 (de) | 1998-05-29 | 2010-07-15 | Jgc Catalysts & Chemicals Ltd | Verfahren zur herstellung photoelektrischer zellen |
CA2337667C (en) | 1998-08-10 | 2008-04-29 | Amgen Inc. | Dextran-leptin conjugates, pharmaceutical compositions and related methods |
JP2002526780A (ja) | 1998-10-02 | 2002-08-20 | アムジエン・インコーポレーテツド | レプチン処置に対する素因の決定方法 |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
NZ512657A (en) | 1999-01-14 | 2004-01-30 | Amylin Pharmaceuticals Inc | Glucagon suppression |
DE60027409T2 (de) | 1999-02-12 | 2007-04-12 | Amgen Inc., Thousand Oaks | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
US6475984B2 (en) * | 1999-04-29 | 2002-11-05 | The Nemours Foundation | Administration of leptin |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
EP1214351A2 (en) * | 1999-09-22 | 2002-06-19 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
JP2001199887A (ja) | 1999-11-10 | 2001-07-24 | Takeda Chem Ind Ltd | 体重増加抑制剤 |
WO2001034200A1 (fr) | 1999-11-10 | 2001-05-17 | Takeda Chemical Industries, Ltd | Inhibiteurs de prise de poids |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
WO2001079480A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
US6492117B1 (en) | 2000-07-12 | 2002-12-10 | Gendaq Limited | Zinc finger polypeptides capable of binding DNA quadruplexes |
US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
DE60237100D1 (de) | 2001-10-22 | 2010-09-02 | Amgen Inc | Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung |
US6899892B2 (en) | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
CN1684990A (zh) | 2002-11-01 | 2005-10-19 | 株式会社德山 | 聚合性组合物、其固化体的制造方法以及光学物品 |
JP4949838B2 (ja) * | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー/エス | 新規glp−1誘導体 |
EP1667724A2 (en) * | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
NZ549332A (en) | 2004-02-11 | 2008-11-28 | Amylin Pharmaceuticals Inc | Amylin family peptides and methods for making and using them |
US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
WO2006059106A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
US7898623B2 (en) | 2005-07-04 | 2011-03-01 | Semiconductor Energy Laboratory Co., Ltd. | Display device, electronic device and method of driving display device |
GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
US20070238669A1 (en) | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
WO2007104789A2 (en) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
KR20080106950A (ko) | 2006-03-31 | 2008-12-09 | 아밀린 파마슈티칼스, 인크. | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 |
EP2035450A2 (en) | 2006-05-26 | 2009-03-18 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CN101113175A (zh) * | 2007-04-28 | 2008-01-30 | 中国科学院西北高原生物研究所 | 鼠兔家族瘦素蛋白及其cDNA序列 |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
EP2190863B1 (en) | 2007-07-31 | 2015-09-02 | Affibody AB | New albumin binding compositions, methods and uses |
GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
US8598314B2 (en) * | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
AU2007360979B2 (en) | 2007-11-14 | 2014-04-10 | Amylin Pharmaceuticals, Llc | Methods for treating obesity and obesity related diseases and disorders |
MX2010008632A (es) * | 2008-02-08 | 2010-08-30 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
JP5703226B2 (ja) | 2008-10-21 | 2015-04-15 | ノヴォ ノルディスク アー/エス | アミリン誘導体 |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
BRPI1006943A2 (pt) | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
KR101331101B1 (ko) * | 2010-06-04 | 2013-11-19 | 에스케이케미칼주식회사 | 인자 vii 활성을 갖는 융합 단백질 |
DK2933262T3 (en) | 2010-07-09 | 2018-06-25 | Affibody Ab | polypeptides |
ES2563091T3 (es) | 2010-09-28 | 2016-03-10 | Amylin Pharmaceuticals, Llc | Polipéptidos modificados genéticamente que tienen duración de acción potenciada |
WO2012050930A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc | Engineered polypeptides having enhanced duration of action |
CN104271588B (zh) | 2011-07-08 | 2017-10-10 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
WO2013009539A1 (en) * | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action and reduced immunogenicity |
-
2011
- 2011-09-28 WO PCT/US2011/053786 patent/WO2012050930A2/en active Application Filing
- 2011-09-28 BR BR112013007385-3A patent/BR112013007385B1/pt active IP Right Grant
- 2011-09-28 BR BR112013007388-8A patent/BR112013007388B1/pt active IP Right Grant
- 2011-09-28 EA EA201390497A patent/EA032917B1/ru unknown
- 2011-09-28 BR BR122021020041-6A patent/BR122021020041B1/pt active IP Right Grant
- 2011-09-28 ES ES11833075.2T patent/ES2630031T3/es active Active
- 2011-09-28 CN CN201180056939.4A patent/CN103547590B/zh active Active
- 2011-09-28 PT PT118330802T patent/PT2621519T/pt unknown
- 2011-09-28 CN CN201180057153.4A patent/CN103403019B/zh active Active
- 2011-09-28 ES ES11833080.2T patent/ES2641869T3/es active Active
- 2011-09-28 EP EP11833075.2A patent/EP2621515B1/en active Active
- 2011-09-28 EP EP11833080.2A patent/EP2621519B1/en active Active
- 2011-09-28 EA EA201390474A patent/EA024507B1/ru unknown
- 2011-09-28 PL PL17163203T patent/PL3241558T3/pl unknown
- 2011-09-28 EP EP17163203.7A patent/EP3241558B1/en active Active
- 2011-09-28 WO PCT/US2011/053774 patent/WO2012050925A2/en active Application Filing
- 2011-09-28 DK DK17163203.7T patent/DK3241558T3/da active
- 2011-09-28 CA CA2813038A patent/CA2813038C/en active Active
- 2011-09-28 CA CA3138758A patent/CA3138758A1/en active Pending
- 2011-09-28 ES ES17163203T patent/ES2873253T3/es active Active
- 2011-09-28 DK DK11833075.2T patent/DK2621515T3/en active
- 2011-09-28 PT PT118330752T patent/PT2621515T/pt unknown
- 2011-09-28 DK DK11833080.2T patent/DK2621519T3/en active
- 2011-09-28 MX MX2013003482A patent/MX351128B/es active IP Right Grant
- 2011-09-28 CA CA2813087A patent/CA2813087C/en active Active
- 2011-09-28 JP JP2013531786A patent/JP6174489B2/ja active Active
- 2011-09-28 JP JP2013531789A patent/JP2014502252A/ja active Pending
- 2011-09-28 EP EP17174544.1A patent/EP3305315A1/en not_active Withdrawn
- 2011-09-28 MX MX2013003472A patent/MX349054B/es active IP Right Grant
-
2013
- 2013-03-28 US US13/852,521 patent/US20130203661A1/en not_active Abandoned
- 2013-03-28 US US13/852,671 patent/US20130274182A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,523 patent/US10087228B2/en active Active
- 2015-07-15 US US14/800,537 patent/US20160137709A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016235165A patent/JP6608799B2/ja active Active
-
2017
- 2017-02-28 JP JP2017036849A patent/JP6412183B2/ja active Active
- 2017-06-28 CY CY20171100690T patent/CY1119023T1/el unknown
- 2017-09-26 CY CY20171101013T patent/CY1119498T1/el unknown
-
2019
- 2019-10-24 JP JP2019193539A patent/JP2020033366A/ja active Pending
-
2020
- 2020-01-24 US US16/751,538 patent/US11535659B2/en active Active
-
2022
- 2022-10-25 US US18/049,445 patent/US20230115655A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013007385A2 (pt) | leptinas altamente solúveis | |
KR101873773B1 (ko) | 류마티즘 관절염 예방 또는 치료 조성물 | |
Li et al. | Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/AlCl3 inducing rats model of Alzheimer’s disease | |
BRPI0506741A (pt) | glicosilação de peptìdeos ligados a o | |
JP2017081939A5 (pt) | ||
BR112014016076B1 (pt) | Peptídeo, vetor, construção de peptídeo quimérico e composição farmacêutica | |
TW200630327A (en) | Substituted phenylalkanoic acids | |
NO20054769D0 (no) | Substituerte fenylalkansyrer | |
BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
JP2013534426A5 (pt) | ||
JP2011530599A5 (pt) | ||
IN2014DN05670A (pt) | ||
MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
BR112012012081A2 (pt) | método para o processamento de um arquivo de imagens médicas kobitidas em um procedimento de imagem guiada por protocolo ,equipamento para o processamento de um arquivo de imagens médicas obtidas por um procedimento de imagem guiada por protocolo e elemamto de programa de computador contendo conjuntos de instruções | |
KR102340761B1 (ko) | Nkx3.2 단편 및 이를 함유하는 약학 조성물 | |
ES2730050T3 (es) | Interleuquina 38 truncada en el extremo terminal N | |
ES2700149T3 (es) | Proteínas de fusión de UTI | |
BRPI0519268A2 (pt) | sulfonamido-macrociclos e sais dos mesmos, uma composiÇço farmacÊutica compreendendo esses compostos, o mÉtodo de preparo e uso dos mesmos | |
MY197684A (en) | Oncolytic virus and method | |
RU2492163C9 (ru) | Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии | |
TW200631949A (en) | Substituted carboxylic acids | |
JP2019532915A (ja) | 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法 | |
WO2014119753A4 (ja) | マイオスタチン阻害ペプチド | |
BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
KR20170022348A (ko) | 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: AMYLIN PHARMACEUTICALS INC. (US) ; ASTRAZENECA PHARMACEUTICALS LP (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |